Elevance Health
About: Elevance Health remains one of the leading health insurers in the US, providing medical benefits to 46 million medical members as of December 2024. The company offers employer, individual, and government-sponsored coverage plans. Elevance differs from its peers in its unique position as the largest single provider of Blue Cross Blue Shield branded coverage, operating as the licensee for the Blue Cross Blue Shield Association in 14 states. Through acquisitions, such as the Amerigroup deal in 2012 and MMM in 2021, Elevance's reach expands beyond those states through government-sponsored programs, such as Medicaid and Medicare Advantage plans, too. It is also an emerging player in pharmacy benefit management and other healthcare services.
Employees: 104,200
0
Funds holding %
of 7,312 funds
0
Analysts bullish %
of 7 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
58% more first-time investments, than exits
New positions opened: 215 | Existing positions closed: 136
36% more call options, than puts
Call options by funds: $801M | Put options by funds: $588M
23% more repeat investments, than reductions
Existing positions increased: 644 | Existing positions reduced: 525
16% more funds holding in top 10
Funds holding in top 10: 37 [Q4 2024] → 43 (+6) [Q1 2025]
15% more capital invested
Capital invested by funds: $75.9B [Q4 2024] → $87B (+$11.1B) [Q1 2025]
3% more funds holding
Funds holding: 1,573 [Q4 2024] → 1,624 (+51) [Q1 2025]
0.79% less ownership
Funds ownership: 88.86% [Q4 2024] → 88.07% (-0.79%) [Q1 2025]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$434
27%
upside
Avg. target
$487
43%
upside
High target
$529
55%
upside
7 analyst ratings
6 positive
86%
1 neutral
14%
0 negative
0%
Barclays Andrew Mok | 27%upside $434 | Overweight Maintained | 9 Jul 2025 |
Truist Securities David Macdonald | 47%upside $500 | Buy Maintained | 9 Jun 2025 |
RBC Capital Ben Hendrix | 40%upside $478 | Outperform Reiterated | 4 Jun 2025 |
Argus Research David Toung | 37%upside $465 | Buy Maintained | 25 Apr 2025 |
Guggenheim Jason Cassorla | 52%upside $518 | Buy Reiterated | 23 Apr 2025 |
Financial journalist opinion
Based on 103 articles about ELV published over the past 30 days
Neutral
PRNewsWire
16 hours ago
ELV Deadline: ELV Investors with Losses in Excess of $100K Have Opportunity to Lead Elevance Health, Inc. Securities Fraud Lawsuit
NEW YORK , July 11, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the "Class Period"), of the important July 11, 2025 lead plaintiff deadline. So what: If you purchased Elevance Health common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
Neutral
GlobeNewsWire
20 hours ago
FINAL ELV DEADLINE ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Elevance Health, Inc. and Urgently Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Elevance Health (ELV) To Contact Him Directly To Discuss Their Options
Neutral
GlobeNewsWire
20 hours ago
ELV DEADLINE TODAY: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Elevance Health, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important July 11 Deadline in Securities Class Action – ELV
NEW YORK, July 11, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Elevance Health, Inc. (NYSE: ELV) between April 18, 2024 and October 16, 2024, both dates inclusive (the “Class Period”), of the important July 11, 2025 lead plaintiff deadline.
Neutral
GlobeNewsWire
21 hours ago
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Elevance Health
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Elevance To Contact Him Directly To Discuss Their Options
Neutral
PRNewsWire
1 day ago
Elevance Health, Inc. (ELV) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOS ANGELES , July 10, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV). IF YOU SUFFERED A LOSS ON YOUR ELEVANCE INVESTMENTS, CLICK HERE BEFORE JULY 11, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT What Is The Lawsuit About?
Neutral
PRNewsWire
1 day ago
DEADLINE TOMORROW: Berger Montague Advises Elevance Health (NYSE: ELV) Investors to Contact the Firm Before July 11, 2025
PHILADELPHIA , July 10, 2025 /PRNewswire/ -- Berger Montague PC advises investors that a securities class action lawsuit has been filed against Elevance Health, Inc. ("Elevance" or the "Company") (NYSE: ELV) on behalf of purchasers of Elevance securities between April 18, 2024 through October 16, 2024, inclusive (the "Class Period"). Investor Deadline: Investors who purchased or acquired Elevance securities during the Class Period may, no later than JULY 11, 2025 , seek to be appointed as a lead plaintiff representative of the class.
Negative
Zacks Investment Research
1 day ago
Earnings Preview: Elevance Health (ELV) Q2 Earnings Expected to Decline
Elevance Health (ELV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neutral
GlobeNewsWire
1 day ago
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Elevance Health, Inc. of Class Action Lawsuit and Upcoming Deadlines - ELV
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or the “Company”) (NYSE: ELV). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext.
Neutral
GlobeNewsWire
1 day ago
ELV COURT NOTICE: Elevance Health, Inc. Investors may have been Affected by Fraud – Contact BFA Law by the July 11 Legal Deadline (NYSE:ELV)
NEW YORK, July 10, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Elevance Health, Inc. (NYSE: ELV) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Elevance you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/elevance-health-inc.
Neutral
GlobeNewsWire
2 days ago
ELV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Elevance Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
NEW YORK, July 09, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Elevance Health, Inc. (“Elevance” or “the Company”) (NYSE: ELV) and certain of its officers.
Charts implemented using Lightweight Charts™